Member Info for Laura2022

0.7p+

They will have a plan , and an unscrupulous one

Unless.one of major holders blocks it

Of course pinch of salt needed ,but this was 1st and only post from back in Feb

Lets see

P140diamond

Posted in: IMM

Posts: 1

Prioritised Patent secure19 Feb 2026 11:36

Morning All,

Excuse my English as 1st language is French. I have viewed the chat on here for past 2 years and thought I will post my opinion. I have a very good relationship with Laura Mauran-Ambrosino and we chat on a regular basis. The patent submission is done and will be a box ticking exercise. It will not be published in a scientific journals until the completion of all the discussions/CDA's etc etc. To publish under current conditions would just be stupid and foolhardy.

The science is fantastic and will revolutionize the autoimmune space. This is why the current status quo is so critical. This work has taken years to develop, I suggest a little more patience. A magnificent partnership deal will be completed, once ALL negotiation/discussions are completed.

This is the worlds 1st immunormaliser. This has been confirmed by Jackson Labs, renowned and totally independent.

This patent is KEY. The many components are time intensive and exhaustive, taking time. I am pleased that IMM remain silent.

I have never felt more confident of the future for IMM.

Take or leave these comments, I will not post again till after the release of the deal and then say told you so !!!!!!!!!!!!!!!!!!!

HM

Same question as last night

Are you a bitter ex holder or just a random new ID

No mention of support for proposal in RNS

Will prob be i the circular later

The favourable impact of P140 on immune system homeostasis also supports P140 as a new potential standard of care for patients suffering from a multitude of autoimmune diseases, that are caused by the same underlying malfunction. This also aligns with many preclinical animal models of autoimmune diseases where P140 has clearly demonstrated efficacy.

 

Based on this recent progress and insights into P140's MOA and autoimmune disease, the Group is in active discussions with a number of potential commercial partners. 

Blue day today

Looks like whatever was weighing on share was lifted yesterday afternoon

At one point could sell my full 93mln shares

1st time ever since holding...where usual maximum was 25mln

And remember

These are already 5mths out of date as for yewr ended Dex

Rreece

Yes, and even then (FY 2024and2025l PYC one of few companies to BOTH years grow revenues

Don't forget ALRT valued at £27mln V RCFX £7.5!!

Crazy disconnect which will narrow and with contracts at 'advanced stages"

Last trading update March 2026 saw RCFX rise 70% ( and now no overhang!!)

The structural case for RC Fornax's services has never been stronger. The UK's transition to a war-fighting readiness posture demands precisely the kind of agile, outcomes-focused capability we deliver. With £5.7m in FY26 revenue visibility, a well-funded balance sheet and a pipeline of high-quality opportunities at advanced stages, I am confident in the Company's ability to deliver a materially improved second half and a stronger full year and beyond

Yes, fact testing ongoing is very vrty positive

Yes KingH

That is a massive jump from c £100k annualised

Invoiced sales in April 2026 were 3x those achieved in September 2025.

• First phase of contract with UK Public Sector Space Client delivered successfully, with exceptional customer feedback and current commercial discussions over a potential second phase.

• Substantial progress made towards a major framework agreement with a top-seven prime contractor to MoD, now in the final stages of commercial approvals.

• Strong commercial execution driving results, with eight new clients (including two top-six prime contractors to MoD), a further Prime framework on track, and a c.2.5x uplift in win rate.

• The Board remains encouraged by long-term UK defence spending trajectory, with spending projected to reach 2.5% of GDP by 2027.

• Total purchase orders received ensure the Company is well positioned to benefit in FY26, FY27 and beyond as procurement clarity improves and framework participation generates increasing revenue opportunities.

Partnering opportunities

· Active discussions continue with a number of potential global commercial partners for P140, with the Company focused on completing a value-enhancing licensing transaction in 2026

· Kapiglucagon also represents a potential future partnering opportunity, supported by its proprietary position, 100% ImmuPharma ownership and strategic flexibility across development, partnering and commercialisation pathways

Eric

They were both buys imho

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that so far this month, it has secured multiple new contract awards with a combined value of over £345,000.

The awards comprise a combination of new and follow-on engagements with respected UK and international biotechnology and oncology-focused organisations, including a NASDAQ-listed clinical-stage biotechnology company, clinical-stage therapeutics developers, and leading cancer research groups. The contracts further reinforce Physiomics' growing reputation as a trusted scientific partner across the biotech and pharmaceutical sectors.

Revenue of £2.2m (H1 FY25 restated: £2.5m), with H1 FY26 revenue 40% ahead of H2 FY25 (£1.6m), reflecting improving order conversion momentum during the Period.

• Outcome-based services represented 72% of revenue mix (H1 FY25 restated: 52%), in line with strategy set out at IPO.

• Average 26% month-on-month increase in revenue during the Period.

Great first post

Hopefully you feel better with that off your chest

Were you a previous holder?

Yes Del

All buys been shown as sells at 42.2p ish last few days

The larger delayed trades paid higher last week

4.42 40,000

4.4395 110,000